Try our Advanced Search for more refined results
Life Sciences
-
April 02, 2026
Georgia Midwifery Laws Violate State Constitution, Suit Says
A trio of midwives are challenging Georgia laws that restrict their ability to practice, arguing that the statutes exacerbate an ongoing maternal health crisis and conflict with the Peach State's constitution.
-
April 02, 2026
Squires Gives Go-Ahead To 5 Patent Reviews, Denies 8
In the latest order summarizing his decisions on requests for America Invents Act patent reviews, U.S. Patent and Trademark Office Director John Squires has granted five petitions and turned down eight others.
-
April 02, 2026
Petition To Repeal Legal Pot Mobilizes A Showdown In Mass.
A campaign to repeal the legalization of retail cannabis in Massachusetts via ballot initiative — the first campaign of its kind in the country — is uniting legalization advocates, entrepreneurs and industry players in a coordinated response to defeat the effort before it spreads to other states.
-
April 02, 2026
Ex-Pharma Exec Hit With $5.3M Fee Award In Del.
The Delaware Chancery Court has ordered a former pharmaceutical executive to pay more than $5.3 million in attorney fees following years of litigation over alleged disloyal conduct and trade secret misuse, concluding that the award is reasonable despite objections that the amount was excessive.
-
April 02, 2026
Alexion Beats Trade Secret Claims In Amyndas Suit
Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.
-
April 02, 2026
Trump Orders 100% Pharma Tariff, Modifies Metals Duties
Later this year, the U.S. will impose 100% tariffs on imported pharmaceuticals, but drug companies could qualify for reduced tariff rates as low as zero if they agree to invest domestically and enter most-favored-nation drug-pricing agreements with the government, according to an executive order President Donald Trump signed Thursday.
-
April 02, 2026
Snell & Wilmer Names Life Sciences Pro As San Diego Leader
Snell & Wilmer LLP has tapped a longtime corporate attorney who specializes in the life sciences industry to be the new head of its San Diego office.
-
April 02, 2026
Teva $35M Delayed Generic Inhalers Deal Gets Initial OK
A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.
-
April 02, 2026
Vape Sellers, Makers Evade Ga. Woman's RICO Scheme Suit
A Georgia federal judge has tossed a suit against numerous vape sellers and makers alleging they conspired to sell vapes with illegal levels of delta-9 THC, saying her complaint fails to allege any kind of scheme, but rather amounts to describing the normal supply chain.
-
April 01, 2026
Ex-Wilson Sonsini M&A Co-Head Rejoins Goodwin In SF
A former partner at Goodwin Procter LLP's Silicon Valley office has rejoined the firm in San Francisco after co-leading Wilson Sonsini Goodrich & Rosati PC's mergers and acquisitions practice for five years, Goodwin announced on Wednesday.
-
April 01, 2026
7th Circ. Says Ill. BIPA Amendment Applies Retroactively
The Seventh Circuit held Wednesday that a liability-limiting amendment to Illinois' biometric privacy law applies to every lawsuit pending at the time the amendment took effect, ruling that the amendment is only a procedural change to the law and, therefore, must be applied retroactively.
-
April 01, 2026
Berkshire Must Defend Trulieve In Worker Death Suit
An insurance company that is a unit of Berkshire Hathaway had an obligation to defend Trulieve Inc. against a Massachusetts wrongful death lawsuit brought by the family of a cannabis worker, a Florida federal judge has ruled, rejecting arguments that the worker wasn't an employee.
-
April 01, 2026
3 Federal Circuit Clashes To Watch In April
The Federal Circuit argument calendar for this month includes Centripetal Networks' appeal of a decision clearing Cisco of infringing cybersecurity patents after a multibillion-dollar award was thrown out, as well as Ecobee's challenge to an $11.5 million infringement verdict involving smart thermostats.
-
April 01, 2026
DC Cannabis Co. Sues Firm Over Botched Grow Facility
A cannabis industry-focused engineering firm reneged on a promise to build a fully operational indoor grow facility for a D.C.-based medical dispensary, the company told a D.C. federal court, claiming it is now stuck with the unfinished project and $1 million in specialized equipment that can't be resold.
-
April 01, 2026
Harvard Researcher Can Get Docs On Prosecution Motives
A Massachusetts federal judge ruled Wednesday that a Harvard Medical School researcher and Russian national charged with smuggling frog embryo specimens can see emails and other documents regarding the government's decision to prosecute her, citing evidence the case was "vindictive."
-
April 01, 2026
Astellas Beats $115M Milestone Claim In Del. Chancery Ruling
A Delaware Court of Chancery judge has ruled that Astellas Pharma Inc. is not obligated to pay up to $115 million in disputed drug development milestone payments tied to its acquisition of Potenza Therapeutics Inc., finding that the clinical trials at issue never met the contract's definition of a Phase II study.
-
April 01, 2026
Mass. Cannabis Businesses Say Repeal Bid Misleads Voters
A coalition of Massachusetts cannabis business owners Wednesday challenged the constitutionality of a proposal to repeal retail marijuana legalization at the ballot box this November.
-
April 01, 2026
PBM Opioid Crisis Suit Stays In Federal Court, Judge Says
A Michigan federal judge on Tuesday denied a request from the state attorney general to remand to state court a suit accusing two pharmacy benefit managers of fueling the opioid crisis, saying the case will remain in federal court because work performed for federal and nonfederal clients cannot be separated.
-
April 01, 2026
CFO Scores $867K Win In Health Device Co. Wage Suit
A wearable health device company must pay its former chief financial officer nearly $867,000 after a Connecticut federal jury determined it stiffed him on his full wages and benefits, according to court filings.
-
March 31, 2026
Split 4th Circ. Affirms Injunction On W.Va. Drug Discount Law
A split Fourth Circuit panel sided with a trio of pharmaceutical manufacturers Tuesday that opposed a West Virginia law addressing drug delivery in the 340B program, saying the law attempted to reshape the "contractual bargain" Congress makes with private parties through its spending powers.
-
March 31, 2026
Novartis Seeks To Block New Wash. 340B Drug-Pricing Law
Novartis has called on a Washington federal judge to block a new state law it claims illegally expands the subsidies manufacturers must pay under the federal government's 340B Drug Pricing Program, arguing drugmakers will lose millions of dollars annually if the law is allowed to take effect in June.
-
March 31, 2026
Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks
Novartis must face a False Claims Act suit alleging it improperly had doctors prescribe its multiple sclerosis drug, a New York federal judge said Monday, finding the relator plausibly pled scienter by bringing evidence that the company "kept meticulous track" of how many prescriptions doctors wrote for the drug.
-
March 31, 2026
Anesthesia Parent Can't Duck Antitrust Suit, But Affiliate Can
The parent company of U.S. Anesthesia Partners Inc. remains in the crosshairs of a private antitrust suit accusing it of trying to monopolize Texas anesthesia services, while a federal judge dismissed for now claims against an affiliate that he said was too far removed from the alleged rollup strategy.
-
March 31, 2026
Moderna, Pfizer Want Bayer's COVID-Shot Patent Suits Tossed
Pharmaceutical giants Moderna and Pfizer-BioNTech have asked a Delaware federal judge to dismiss lawsuits seeking to recover royalties from sales of their respective COVID-19 vaccines, which plaintiff Bayer claims were made possible via infringement of its patent.
-
March 31, 2026
BioPharma Spoofing Suit Against Canadian Banks Proceeds
A New York federal judge has ruled that Quantum BioPharma Ltd. can pursue most of its lawsuit accusing the brokerage arms of the Royal Bank of Canada and the Canadian Imperial Bank of Commerce of spoofing the biopharmaceutical company's stock, finding that Quantum plausibly alleged that the scheme occurred and that the banks acted recklessly.
Expert Analysis
-
Utah's AI Prescription Renewal Pilot Could Inform Policy
Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.
-
Ramped Up Psychedelic Production Carries Opportunity, Risk
Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.
-
Series
Teaching Logic Makes Me A Better Lawyer
Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.
-
New Biotech Nat'l Security Controls May Have Blunted Impact
While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.
-
From IPR To EPR: The Rapid Rise Of Ex Parte Reexamination
With the current administration's dramatic shifts in policy rendering inter partes reviews essentially unavailable for the majority of patents being asserted in litigation, IPR filing rates have plunged, and ex parte reexamination requests have surged to the average rate of IPR petitions in 2024, say attorneys at McKool Smith.
-
Series
Law School's Missed Lessons: Practicing Resilience
Resilience is a skill acquired through daily practices that focus on learning from missteps, recovering quickly without internalizing defeat and moving forward with intention, says Nicholas Meza at Quarles & Brady.
-
Takeaways From The DOJ Fraud Section's 2025 Year In Review
Former acting Principal Deputy Chief Sean Tonolli of the U.S. Department of Justice's Fraud Section, now at Cahill Gordon, analyzes key findings from the section’s annual report — including the changes implemented to adapt to the new administration’s priorities — and lays out what to watch for this year.
-
Upshot Of 'Skinny Label' Case May Go Beyond Pharma
The U.S. Supreme Court's pending review of Hikma v. Amarin, over a drugmaker's "skinny label," carries implications for both generics and brand-name pharmaceutical manufacturers, and could shed light on how inducement doctrine should operate in other regulated industries where products have substantial lawful uses, says Jason Shull at Banner Witcoff.
-
Assessing Factors Behind Biosimilar Uptake And Competition
As biosimilar uptake remains uneven and questions linger over whether the Biologics Price Competition and Innovation Act can deliver robust competition between biologics and biosimilars, a case study of Humira and its biosimilars illustrates how many factors, including payor reimbursement and formulary strategy, collectively shape competitive dynamics, say analysts at Analysis Group.
-
Traditional FCA Enforcement Surges Amid Shifting Priorities
The U.S. Department of Justice’s January report on False Claims Act enforcement in fiscal year 2025 reveals that while the administration signaled its intent to expand FCA enforcement into new areas such as tariffs, for now the greatest exposure remains in traditional areas like healthcare — in which the risk is growing, say attorneys at Debevoise.
-
NYC Bar Opinion Warns Attys On Use Of AI Recording Tools
Attorneys who use artificial intelligence tools to record, transcribe and summarize conversations with clients should heed the New York City Bar Association’s recent opinion addressing the legal and ethical risks posed by such tools, and follow several best practices to avoid violating the Rules of Professional Conduct, say attorneys at Smith Gambrell.
-
Series
The Biz Court Digest: Dispatches From Utah's Newest Court
While a robust body of law hasn't yet developed since the Utah Business and Chancery Court's founding in October 2024, the number of cases filed there has recently picked up, and its existence illustrates Utah's desire to be top of mind for businesses across the country, says Evan Strassberg at Michael Best.
-
Checking In On Biologics-Related Patent Review Trends
Comprehensive analysis of Patent Trial and Appeal Board data since the PTAB's creation indicates that while inter partes review and post-grant review are potent weapons for challenging biologics-related patents, recent policy changes may reduce their effectiveness, say attorneys at Steptoe.
-
4 Quick Emotional Resets For Lawyers With Conflict Fatigue
Though the emotional wear and tear of legal work can trap attorneys in conflict fatigue — leaving them unable to shake off tense interactions or return to a calm baseline — simple therapeutic techniques for resetting the nervous system can help break the cycle, says Chantel Cohen at CWC Coaching & Therapy.
-
Rescheduling Cannabis Marks New Tax Era For Operators
As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.